All cell lines were purchased from ATCC and maintained at 37°C and 5% CO
2 in Dulbecco’s modified Eagle’s medium (DMEM, 4.5 g/L glucose), supplemented with 10% fetal bovine serum, non-essential amino acids, 1% Penicillin (100 mg/ml) and streptomycin (100 mg/mL) antibiotics.
Mouse anti-Ki-67,
rabbit anti-phospho-ERK1/2,
ERK1/2, p21
waf/cip, and
HMGA2 antibodies were purchased from Cell Signaling Technologies, Inc (Boston, MA, USA). Mouse anti-p16
INK4A antibody was purchased from Sigma (St. Louis, MO, USA), Mouse anti-phospho H2AX antibody was purchased from EMD Millipore (Darmstadt, Germany), and rabbit anti-H2AX antibody was purchased from Abcam (Cambridge, MA, USA). Horse anti-mouse and goat anti-rabbit secondary antibodies were purchased from Cell Signaling Technologies, Inc. (Boston, MA, USA).
NS1643 was purchased from Alomone Labs (Jerusalem, Israel), EGTA was purchased from Calbiochem (San Diego, CA, USA),
TEMPOL was purchased from Sigma (St. Louis, MO, USA) and
E-4031 was purchased from Abcam (Cambridge, MA, USA).
Fukushiro-Lopes D.F., Hegel A.D., Rao V., Wyatt D., Baker A., Breuer E.K., Osipo C., Zartman J.J., Burnette M., Kaja S., Kouzoukas D., Burris S., Jones W.K, & Gentile S. (2017). Preclinical study of a Kv11.1 potassium channel activator as antineoplastic approach for breast cancer. Oncotarget, 9(3), 3321-3337.